AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studySystematic reviewPeer review unconfirmed
Human Studies on BCG Vaccine in Multiple Sclerosis
A systematic review found that BCG vaccine shows promising immunomodulatory potential for multiple sclerosis, based on its historical and immunological context.
- Tags
- #MSResearch
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
This finding is significant as it suggests BCG could play a role in treating autoimmune diseases like multiple sclerosis, expanding its therapeutic applications beyond infectious diseases.
What this does not prove
The review does not provide definitive evidence for BCG's efficacy in treating multiple sclerosis, leaving gaps in knowledge regarding its actual effect.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-15
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceThe BCG Vaccine: Pharmacological Biotechnology and Expanding Immunological Horizons. ↗DOI: 10.31083/fbe49594
Supporting passages (5)
study designThis review examines the historical development, biotechnological production, immunological mechanisms, and expanding therapeutic applications of BCG.
subjectsBeyond TB, BCG remains a cornerstone immunotherapy for non-muscle-invasive bladder cancer and shows promising immunomodulatory potential in autoimmune diseases such as type 1 diabetes and multiple sclerosis.
findingsBeyond TB, BCG remains a cornerstone immunotherapy for non-muscle-invasive bladder cancer and shows promising immunomodulatory potential in autoimmune diseases such as type 1 diabetes and multiple sclerosis.
publication datePublication date: 2026-09-15
limitationsTitle: The BCG Vaccine: Pharmacological Biotechnology and Expanding Immunological Horizons.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.